London, 17 March 2015 – TechNavio has announced the publication of a new market research report on the Global Gaucher Disease Market, which is expected to grow at a CAGR of 7.60 percent from 2014-2019.
About the Report
The latest report by TechNavio focuses on diseases that affect a small percentage of the population and are backed by few marketed drugs. Regions like US and European Union have a provision for ‘orphan drug designation’, where orphan drugs enjoy protocol assistance and a 10 year market exclusivity.
“Market exclusivity is a commercially beneficial provision that is increasingly attracting pharmaceutical companies to work for orphan diseases,” says Faisal Ghaus, Vice President of TechNavio.
“The entry of generic drugs is barred for the duration of market exclusivity, so as to protect the market sales of an orphan drug.”
Furthermore, the report emphasizes the increasing regulatory assistance in emerging nations. Developing countries are making various legislative changes to promote research on orphan diseases. These countries are also working towards providing incentives like reimbursements to pharmaceutical manufacturers to encourage research in this area.
“Taiwan and South Korea have already implemented regulations regarding orphan drug designation while countries like India are still working on this area,” says Ghaus.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2019
Market Growth Drivers:
- Special Provisions for Orphan Drugs
- For a full detailed list, view our report.
Market Challenges:
- Limited Patient Population
- For a full detailed list, view our report.
Market Trends:
- Regulatory Assistance in Emerging Nations
- For a full detailed list, view our report.
Key Vendors:
- Actelion Pharmaceuticals Ltd.
- Genzyme Corp.
- Pfizer Inc.
- Shire plc
Other Prominent Vendors:
- Amicus Therapeutics
- Belrose Pharma
- Bionaturis
- ISU Abxis
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
